Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression

Psychedelic-assisted therapy is conceptualised by the authors as a distinctive form of drug‑assisted psychotherapy in which a small number of high‑dose dosing sessions, embedded within psychological preparation and integration, are intended to facilitate a profound, potentially transformative psychological experience. Previous studies and clinical reports suggest that such profound or "mystical‑type" experiences, which can be measured with psychometric instruments developed from research on spontaneous and drug‑induced peak experiences, are predictive of longer‑term improvements in mental health across a range of indications. However, it has remained unclear whether specific dimensions of the acute psychedelic experience—particularly Oceanic Boundlessness (OBN, sharing features with mystical‑type experience) and Dread of Ego Dissolution (DED, related to anxiety and impaired cognition)—are the elements most strongly associated with therapeutic benefit, as distinct from more generic sensory/perceptual effects. Jha and colleagues therefore set out to test whether the quality of the acute psilocybin experience predicts subsequent reductions in depressive symptoms in a clinical sample with treatment‑resistant depression (TRD). The primary hypothesis was that higher OBN and lower DED during the high‑dose psilocybin session would predict greater improvement on the self‑rated Quick Inventory of Depressive Symptoms (QIDS‑SR) at a 5‑week endpoint, and that the relationship between OBN and outcome would be stronger than that for perceptual dimensions of altered experience.

The study was an open‑label clinical trial of psilocybin‑assisted therapy conducted in a UK research setting with regulatory and ethics approvals in place. Inclusion criteria required participants to have major depression of at least moderate severity (HAM‑D ≥ 16) with inadequate response to at least two adequate antidepressant courses; participants were asked to be free of antidepressant medication for at least 2 weeks before the trial. Twenty patients were enrolled and underwent two dosing sessions a week apart (10 mg oral psilocybin first, then 25 mg). Nineteen completed the study (6 female; mean age 44.7 ± 10.9 years; range 27–64). Sessions used a supportive, non‑directive therapeutic approach with two therapists, a pre‑session preparation meeting one week before the first dose, and integration sessions 1 day and 1 week after the 25 mg session. During dosing, participants lay with eyes closed and listened to a music programme selected by the research team. The primary clinical outcome for this analysis was the self‑rated 16‑item QIDS‑SR measured at baseline, 1 day, 1 week and the primary endpoint at 5 weeks after the 25 mg session; the 5‑week time point was selected because later follow‑up assessments were confounded by some participants receiving new treatments. Secondary outcomes included QIDS‑SR at later time points, clinician‑rated HAM‑D, Beck Depression Inventory (BDI), measures of trait anxiety (STAI), dysfunctional attitudes (DAS), optimism (LOT‑R) and anhedonia (SHAPS) at various post‑treatment time points. Acute subjective experience during the 25 mg session was measured retrospectively near the session end (~5–6 hours post ingestion) using the 94‑item Altered States of Consciousness questionnaire (ASC). The ASC can be scored as five dimensions—Oceanic Boundlessness (OBN), Dread of Ego Dissolution (DED), visionary restructuralization (VRS), auditory alterations (AUA) and vigilance reduction (VIR)—and into 11 subdimensions derived from OBN, DED and VRS. A threshold of OBN > 0.6 was used to define a "complete" OBN, a cut‑off comparable to thresholds used for mystical‑experience measures in other studies. An in‑house 29‑item Psychedelic Questionnaire (PQ) was also completed for exploratory item‑level correlations. The main statistical approach used repeated measures analysis of variance (GLM with repeated measures in SPSS v24), with Time (baseline, 1 day, 1 week, 5 weeks) as the within‑subject factor and QIDS‑SR as the dependent variable. OBN and DED scores from the ASC were entered as covariates; the primary effects of interest were the Time × OBN and Time × DED interactions, with simple contrasts comparing each post‑treatment level to baseline. Additional analyses included Pearson correlations, group comparisons of responders (≥50% QIDS‑SR reduction) versus non‑responders, regression modelling predicting QIDS‑SR at 5 weeks from OBN and DED, and exploratory item‑level correlations between ASC/PQ items and clinical outcomes.

Nineteen participants completed the trial and provided ASC and clinical outcome data for analysis. Sphericity was assumed for the repeated measures ANOVA (Mauchly's W = 0.71, p = 0.411). For the primary analyses, both the Time × OBN and Time × DED interactions were statistically significant at the within‑subject level, and within‑subject contrasts comparing each follow‑up to baseline were significant (p < 0.05), supporting the primary hypothesis that these acute experience dimensions relate to change in depressive symptoms over time. Regression analysis using QIDS‑SR at 5 weeks as the dependent variable and OBN and DED as predictors indicated that together they accounted for a substantial proportion of variance in outcome (R2 = 0.59, adjusted R2 = 0.54). Standardised beta coefficients were reported as 0.605 for OBN (positive association with clinical improvement) and −0.649 for DED (negative association). Based on the standard response threshold (≥50% reduction in QIDS‑SR from baseline), the 5‑week response rate was 47% (n = 9). Comparative and specificity analyses found that OBN was a significantly stronger predictor of reductions in depressive symptoms at 5 weeks than the perceptual ASC dimensions: OBN outperformed visionary restructuralization (VRS) and auditory alterations (AUA) (z = 1.64 and z = 2.01, respectively; p < 0.05). Using the pre‑specified threshold to define "complete" OBN (OBN > 0.6), 11 participants met that criterion (mean OBN = 0.83 ± 0.10) and eight did not (mean OBN = 0.33 ± 0.16); those with complete OBN showed better outcomes across a number of secondary measures and time points (1 day, 1 week, 5 weeks, 3 months and 6 months), and higher response rates, as presented descriptively by the authors. Exploratory item‑level analyses of all 94 ASC items and 29 PQ items showed that items most strongly associated with OBN correlated most strongly with positive clinical outcomes, whereas sensory/perceptual items correlated less with improvement; items reflecting anxiety were associated with worse outcomes. The extracted text notes that none of the patients experienced a worsening of clinical symptoms at 5 weeks.

Jha and colleagues interpret their findings as supporting the hypothesis that the quality of the acute psychedelic experience—specifically high Oceanic Boundlessness and low Dread of Ego Dissolution—predicts beneficial longer‑term clinical outcomes after psilocybin therapy in treatment‑resistant depression. They note that these results replicate prior observations linking psychedelic‑induced mystical‑type or peak experiences with therapeutic benefit, and that the relationship appears to be at least partly specific: mystical‑type features (OBN) were more predictive than generic visual or auditory perceptual effects. The investigators caution, however, that causal claims should be made carefully. While the occurrence of OBN and low DED correlated with clinical improvement and together explained a substantial fraction of variance in change at 5 weeks, unmeasured factors that occur before, during or after dosing could also mediate outcomes. The authors list several candidate mediators including emotional insight or catharsis, suggestibility or priming, re‑experiencing of trauma or life events, insights about self and relationships, the role of music, the patient's ability to "let go", the quality of the therapeutic relationship, and the degree of closure achieved in integration work. They emphasise that these factors may interact with the acute experience and with different psychological frameworks, and that current psychological constructs have not been comprehensively operationalised in this context. Measurement limitations are discussed: existing instruments such as the ASC and the Challenging Experience Questionnaire (CEQ) may not sensitively capture whether a difficult acute experience was successfully resolved, which may be crucial for longer‑term benefit. The authors suggest developing scales that better assess emotional breakthrough after struggle. At a neurobiological level, they outline a conceptual framework linking 5‑HT2A receptor signalling, increased cortical entropy and a brain state closer to criticality under psychedelics, proposing that enhanced sensitivity to context may be a mechanistic component that renders the acute experience therapeutically potent. Practical implications highlighted by the authors include the importance of minimising anxiety, encouraging psychological openness, and optimising preparation and set and setting to foster beneficial experiences. Key limitations acknowledged in the discussion are the small sample size, the exploratory nature of some analyses, and the need for larger, more systematic studies to measure multiple potential predictive factors. The authors conclude that, if replicated, these findings imply that promoting a particular quality of acute experience may be central to therapeutic success in psychedelic therapy and that further work should aim to refine subjective and biological measures of these high‑level experiential states.